Idrevloride clinical trials
Also written VX-371 and GS-5737.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses idrevloride is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Parion Sciences (3) · Gilead Sciences (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses idrevloride is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clearing Lungs With ENaC Inhibition in Primary Ciliary DyskinesiaCompletedPhase 2Parion SciencesNCT02871778Written as VX-371
- A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationCompletedPhase 2Parion SciencesNCT02709109Written as VX-371 + HS
- Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)CompletedPhase 2Parion SciencesNCT02343445Written as P-1037
- Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CFCompletedPhase 1Gilead SciencesNCT01840735Written as GS-5737
- A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy SubjectsTerminatedPhase 1Gilead SciencesNCT01793649Written as GS-5737
Codes
What other systems call idrevloride · ClinicalTrials.gg INT017423
- UNII (FDA) NY2J56S3YAIDREVLORIDEOne source FDA
- NCI Thesaurus C184934IdrevlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NY2J56S3YA | IDREVLORIDE | One source FDA |
| NCI Thesaurus | C184934 | Idrevloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.